Incanthera ltd
WebFeb 2, 2014 · Incanthera has raised a total of £650K in funding over 1 round. This was a Venture - Series Unknown round raised on Feb 2, 2014. Incanthera is funded by The North … WebIncanthera Ltd (Incanthera) is a biopharmaceutical company that discovers and develops therapeutic products for the treatment of cancer. The companys drug candidates under development include ICT2588, a vascular disrupting agent, based on the tumor-blasting technology; and ICT03 Es5, a targeted bioreductive agent; which are targeted at ...
Incanthera ltd
Did you know?
WebFeb 28, 2024 · Developer Incanthera Class Antineoplastics; Colchicum alkaloids; Drug conjugates; Peptides Mechanism of Action Vascular disrupting agents Orphan Drug Status No New Molecular Entity Yes Highest Development Phases No development reported Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer Most Recent Events WebThe ICT has already successfully used this technology to improve the therapeutic index of a colchicine derivative (ICT2588, see Cancer Research, 2010, 70, 6902-6912), which is now licensed to University of Bradford spin-out company Incanthera Ltd (www.incanthera.com) and received global press coverage at the British Science Festival 2011 (e.g ...
WebJun 12, 2024 · Incanthera Ltd Pre-IPO research – targeting the warheads 12 Jun 2024 / Corporate research By Dr Martin Hall, Dr Dorothea Hill, Dr Gregoire Pave. Download full report. Incanthera is a spin-out from the University of Bradford’s Institute of Cancer Therapeutics to exploit development opportunities being generated from this prestigious ... WebDeveloped by Prof Robert Falconer, Prof Paul Loadman and jointly funded by Cancer Research UK and Yorkshire Cancer Research the technology formed the basis for the launch of Incanthera Ltd (now plc), an ICT/University of Bradford spin-out company and now licenced to Ellipses Pharma.
WebIncanthera PLC is a UK-based, dermatology and oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer. Deep dive We explore the... WebIncanthera PLC is a UK-based, dermatology and oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer. In …
WebN4 Pharma top competitors include: Ailse Oncology Ltd, Vaccicure Ltd, Incanthera Ltd, InnoCore How do I contact N4 Pharma? N4 Pharma contact info: Phone number: +44 1332690061 Website: www.n4pharma.com What does N4 Pharma do?
WebIncanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, … oras armaturerWebIn pursuit of best-in-class small molecule drugs to treat cancer and immunologic diseases iplanet showroomWebIncanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies. View what we do SOL … Incanthera is a UK-based, dermatology and oncology therapeutics company focusing … The Company’s strategy of Acquire, Prepare, Commercialise is built on … Financial Calendar. December 07th , 2024 Half-yearly results for the six months … Latest from Incanthera. 2024; 2024; 2024; Archive March 13th, 2024 Director’s … Head Office: Incanthera Ltd 76 King Street Manchester M2 4NH, UK T: 0161 817 … The sustainability of Incanthera is evident in its mission statement: Transformative … The Company has created and continues to develop a rich pipeline of proprietary, … We are not currently recruiting at this time. If you would like to get in touch, please … Financial Calendar. December 07th , 2024 Half-yearly results for the six months … oras expert beltWebSnapshot. Incanthera says its interim results show strong financial control through the six-month period. Incanthera looking at big opportunity as Sol impresses in tests. Incanthera present results of first full year as public company on AQSE. Open Deep dive. iplanet store pondicherryWebNov 8, 2015 · This report provides comprehensive information on the current therapeutic developmental pipeline of Incanthera Ltd.’s, complete with comparative analysis at … iplanet kathriguppe contact numberWebMar 10, 2014 · North West oncology company Incanthera Ltd has acquired University of Salford drug discovery spin-out Onco-NX Ltd. The deal represents the first successful sale of a spin-out company from the University and will see both companies combine their expertise in targeted anticancer drugs, to develop a ground-breaking, therapeutics pipeline. iplanet mall of travancoreiplanit cwcwe